SEBI Registration No - INA000003197 Investment in stock and commodity market are subject to market risk. Please do not trade on those tips which are not provided through SMS.

Blog

cadila

Cadila gets approval for gMedrol and gSensipar

Cipla and Aurobindo have also received approval to make this drug in March 2018. This is a sizable drug in size with $1.7bn sales in 2017 for Amgen.

Cadila Healthcare’s subsidiary Zydus Pharms USA Inc has received USFDA approval to manufacture Cinacalcet HCL and Methylprednisolone.

Methylprednisolone is currently marketed under brand Medrol, however this drug is already off patent. The drug has a small size and Cadila should be able to make $1-2mn from this drug in the US market.

Cinacalcet HCL is sold under brand Sensipar by Amgen Inc. Sensipar generated $1.7bn global sales in 2017 for Amgen. The first patent (primary patent) on this drug had expired on March 08, 2018, two second patents are still remaining, which will expire in 2026. Indian companies Cipla and Aurobindo have also received approval to make this drug in March 2018.

As the drug continues to be protected by secondary patents, it will be interesting to see when these companies launch the drug.

Confirm your financial future with best service advantages of Ripples Advisory Private Limited and here we provide best recommendations for you SUBSCRIBE NOW >> Bonaz Capital